Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48–57.

CAS  PubMed  Google Scholar 

Joller N, et al. Cutting edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions. J Immunol. 2011;186(3):1338–42.

CAS  PubMed  Google Scholar 

Johnston RJ, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26(6):923–37.

CAS  PubMed  Google Scholar 

Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004.

CAS  PubMed  PubMed Central  Google Scholar 

Manieri NA, Chiang EY, Grogan JL. TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol. 2017;38(1):20–8.

CAS  PubMed  Google Scholar 

Chauvin JM, et al. TIGIT and PD-1 impair tumor antigen-specific CD8<SUP>+</SUP>T cells in melanoma patients. J Clin Investig. 2015;125(5):2046–58.

PubMed  PubMed Central  Google Scholar 

Zhang Q, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723.

CAS  PubMed  Google Scholar 

Solomon BL, Garrido-Laguna I. TIGIT: a novel immunotherapy target moving from bench to bedside. Cancer Immunol Immunother. 2018;67(11):1659–67.

CAS  PubMed  PubMed Central  Google Scholar 

Liang RP, et al. TIGIT promotes CD8 T cells exhaustion and predicts poor prognosis of colorectal cancer. Cancer Immunol Immunother. 2021;70(10):2781–93.

CAS  PubMed  PubMed Central  Google Scholar 

Kong YX, et al. T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8 T-cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res. 2016;22(12):3057–66.

CAS  PubMed  Google Scholar 

Pawlowska A, et al. The dual blockade of the TIGIT and PD-1/PD-L1 pathway as a new hope for ovarian cancer patients. Cancers. 2022;14(23):5757.

CAS  PubMed  PubMed Central  Google Scholar 

Perales O, et al. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunol Immunother. 2024;73(10):192.

CAS  PubMed  PubMed Central  Google Scholar 

Dougall WC, et al. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276(1):112–20.

CAS  PubMed  Google Scholar 

Stengel KF, et al. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires receptor clustering. Proc Natl Acad Sci USA. 2012;109(14):5399–404.

CAS  PubMed  PubMed Central  Google Scholar 

Wen J, et al. A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment. Sci Rep. 2021;11(1):22502.

CAS  PubMed  PubMed Central  Google Scholar 

Gao J, et al. CD155, an onco-immunologic molecule in human tumors. Cancer Sci. 2017;108(10):1934–8.

CAS  PubMed  PubMed Central  Google Scholar 

Eichberger J, et al. TIGIT expression on intratumoral lymphocytes correlates with improved prognosis in oral squamous cell carcinoma. Biomedicines. 2022;10(12):3236.

CAS  PubMed  PubMed Central  Google Scholar 

Ge ZH, et al. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 2021;12:699895.

CAS  PubMed  PubMed Central  Google Scholar 

Hooijmans CR, et al. SYRCLE’s risk of bias tool for animal studies. Bmc Med Res Methodol. 2014;14:43.

PubMed  PubMed Central  Google Scholar 

Shaffer T, Natarajan A, Gambhir SS. PET imaging of TIGIT expression on tumor-infiltrating lymphocytes. Clin Cancer Res. 2021;27(7):1932–40.

CAS  PubMed  Google Scholar 

Vincze SR, et al. ImmunoPET imaging of TIGIT in the glioma microenvironment. Sci Rep. 2024;14(1):5305.

CAS  PubMed  PubMed Central  Google Scholar 

Mohr P, et al. Advances and challenges in immunoPET methodology. Front Nucl Med. 2024;4:1360710.

PubMed  PubMed Central  Google Scholar 

Zeven K, et al. Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT. Front Immunol. 2023;14:1268900.

CAS  PubMed  PubMed Central  Google Scholar 

Wang XB, et al. Preclinical and exploratory human studies of novel Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers. Eur J Nucl Med Mol Imaging. 2022;49(8):2584–94.

CAS  PubMed  PubMed Central  Google Scholar 

Weng DH, et al. Peptide-based PET imaging agent of tumor TIGIT expression. Ejnmmi Res. 2023;13(1):38.

CAS  PubMed  PubMed Central  Google Scholar 

Wang J, et al. Development and characterisation of [F]TTDP, a novel T cell immunoglobulin and ITIM domain tracer, in humanised mice and non-human primates. Eur J Nucl Med Mol Imaging. 2025;52(2):416–26.

PubMed  Google Scholar 

Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60(12):1421–34.

CAS  PubMed  PubMed Central  Google Scholar 

de Ruijter LK, et al. Whole-body CD8(+) T cell visualization before and during cancer immunotherapy: a phase 1/2 trial. Nat Med. 2022;28(12):2601–10.

Google Scholar 

Giles JR, et al. CD8+T cells in the cancer-immunity cycle. Immunity. 2023;56(10):2231–53.

CAS  PubMed  PubMed Central  Google Scholar 

Simon S, et al. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. J Immunother Cancer. 2020;8(2):e001631.

PubMed  PubMed Central  Google Scholar 

Krummel MF, Bartumeus F, Gérard A. T cell migration, search strategies and mechanisms. Nat Rev Immunol. 2016;16(3):193–201.

CAS  PubMed  PubMed Central  Google Scholar